BRAF^V600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study

Figures & data

Table 1 Patient characteristics at enrollment

Characteristic	Tumor type
	Overall (N=548)	Breast cancer (n=86)	NSCLC (n=71)	Colorectal cancer (n=75)	Ovarian cancer (n=68)	Prostate cancer (n=21)	Multiple myeloma (n=31)	Biliary tract cancera (n=16)	Other cancers (n=180)
Age, median (min–max), years	64 (21–91)	59 (39–89)	65 (41–88)	64 (30–90)	65 (43–89)	70 (59–80)	65 (40–86)	59 (38–87)	66 (21–91)
Sex, n (%)
Male	221 (40)	2 (2)	38 (54)	36 (48)	0	21 (100)	18 (58)	7 (44)	99 (55)
Female	327 (60)	84 (98)	33 (46)	39 (52)	68 (100)	0	13 (42)	9 (56)	81 (45)
Race, n (%)
White	485 (89)	70 (81)	59 (83)	68 (91)	62 (91)	19 (90)	28 (90)	15 (94)	164 (91)
Black	47 (9)	13 (15)	10 (14)	4 (5)	5 (7)	2 (10)	2 (6)	1 (6)	10 (6)
Asian	9 (2)	3 (3)	2 (3)	0	0	0	0	0	4 (2)
Other	7 (1)	0	0	3 (4)	1 (1)	0	1 (3)	0	2 (1)
Number of previous lines of therapy, median (min–max)	2 (1–15)	3 (1–14)	2 (1–6)	2 (1–8)	4 (1–15)	4 (1–8)	3 (1–10)	2 (1–3)	2 (1–14)
Number of previous lines of therapy, n (%)
1	131 (24)	18 (21)	22 (31)	15 (20)	7 (10)	2 (10)	5 (16)	4 (25)	58 (32)
2	154 (28)	18 (21)	27 (38)	27 (36)	13 (19)	4 (19)	10 (32)	6 (38)	49 (27)
3	89 (16)	11 (13)	12 (17)	16 (21)	13 (19)	4 (19)	3 (10)	4 (25)	26 (14)
4	55 (10)	7 (8)	5 (7)	11 (15)	8 (12)	4 (19)	2 (6)	0	18 (10)
≥5	102 (19)	32 (37)	5 (7)	5 (7)	27 (40)	7 (33)	11 (35)	0	15 (8)
Prior cancer treatment, n (%)
Surgical resection	355 (65)	72 (84)	26 (37)	66 (88)	64 (94)	14 (67)	2 (6)	9 (56)	102 (57)
Systemic therapy	531 (97)	86 (100)	71 (100)	74 (99)	68 (100)	21 (100)	31 (100)	14 (88)	166 (92)
Radiation therapy	256 (47)	65 (76)	43 (61)	28 (37)	10 (15)	16 (76)	15 (48)	5 (31)	74 (41)

Notes:

a Includes cholangiocarcinoma/cancers of biliary tract; tumors of the gallbladder were classified as “other”.

Abbreviations: min, minimum; max, maximum; NSCLC, non-small cell lung cancer.

Table 2 BRAF^V600 mutations overall and by tumor type

BRAF mutationa	Tumor type
	Overall (N=548)	Breast cancer (n=86)	NSCLC (n=71)	Colorectal cancer (n=75)	Ovarian cancer (n=68)	Prostate cancer (n=21)	Multiple myeloma (n=31)	Biliary tract cancerb (n=16)	Other cancers (n=180)
BRAF^V600E, n (%)	16 (3)	0	2 (3)	8 (11)	0	0	1 (3)	1 (6)	4 (2)
[95% CI]	[1.7–4.7]		[0.3–9.8]	[4.7–19.9]			[0.1–16.7]	[0.2–30.2]	[0.6–5.6]

Notes:

a No other BRAF^V600 mutations were identified; V600K, V600R, V600D, and other V600 mutations were screened for.

b Includes cholangiocarcinoma/cancers of the biliary tract; tumors of the gallbladder were classified as “other”.

Abbreviations: CI, confidence interval (based on Clopper–Pearson estimate); NSCLC, non-small cell lung cancer.

Figure S1 CONSORT diagram.

Notes: ^aScreening population is defined as patients who had signed the informed consent. ^bEnrolled population is defined as patients who met the inclusion/exclusion criteria or provided the tumor samples. ^cEvaluable population is defined as enrolled patients with mutation results from the sampling/biopsy procedures.

Abbreviations: CNS, central nervous system; CRC, colorectal cancer; ECOG PS, Eastern Cooperative Oncology Group Performance Status; NSCLC, non-small cell lung cancer.

Table S1 List of other tumor types screened

Tumor type	Patients (n)
Pancreatic cancer	31
Renal cancer	17
SCLC	15
Unknown primary	14
Gastric cancer	13
Bladder cancer	12
Esophageal cancera	12
Soft tissue sarcoma	12
Liver cancer	9
Head and neck cancer	8
Peritoneal cancer	8
Endometrial cancer	6
Sarcoma NOS	6
Chondrosarcoma	4
Gallbladder cancer	4
Glioma	4
Thymic cancer	4
Thyroid cancer	4
Neuroendocrine cancer	4
Small intestine	3
Ampullary cancer	3
Brain cancer	3
Cervical cancer	3
CLL	3
Mesothelioma	3
Vulvovaginal cancer	3
Appendiceal cancer	2
Lung cancer NOS	2
Merkel cell carcinoma	2
Penile cancer	2
Abdominal cancer	1
Adrenocortical carcinoma	1
Anal cancer	1
Ewing’s sarcoma	1
Fallopian tube cancer	1
Giant cell sarcoma of bone	1
Langerhans cell histiocytosis	1
Osteosarcoma	1
SCC of the skin	1
Testicular cancer	1

Note:

a Includes cancer of the gastroesophageal junction.

Abbreviations: CLL, chronic lymphocytic leukemia; NOS, not otherwise specified; SCC, squamous cell carcinoma; SCLC, small cell lung cancer.